BSEAGM/EGM4d ago · 30 Jul 2026, 05:00 pm
Notice of 33rd Annual General Meeting for the Financial Year 2025-26.
Oxygenta Pharmaceutical Ltd · 524636
✦ AI SummaryResults
Oxygenta Pharmaceutical Ltd submitted a notice of its 33rd Annual General Meeting for the financial year 2025-26, scheduled to be held on August 21, 2026, through video conferencing. The meeting will consider and adopt the audited financial statements for the year ended March 31, 2026, and appoint a director in place of Mr. Balasubba Reddy Mamilla, who retires by rotation.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk3/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Oxygenta Pharmaceutical Ltd - 524636 - Submission Of Notice Of 33Rd Annual General Meeting For The Finanical Year 2025-26.
Attachments (1)
📄pdf
Download →
2a269c95-e426-46f0-908d-01776bcf7752.pdf
View document text
VIRUPAKSHA
To Date: 30.07.2026
The Manager
BSE Limited
P.J. Towers, Dalal Street
Mumbai-400001
Dear Sit/ Madam,
Sub: Submission of Notice of 33" Annual General Meeting for the Financial Year 2025-26 under
Regulation 34 of SEBI (LODR) Regulations, 2015.
Unit: Oxygenta Pharmaceutical Limited
In Compliance with Regulation 34 of SEBI (LODR) Regulations, 2015, we are herewith submitting the
Notice of the 33 Annual General Meeting for the Financial Year 2025-26. The Annual General
Meeting of the Company is scheduled to be held on Friday, 21* August, 2026 at 10:30 A.M. through
Video Conference “VC” / Other Audio-Visual Means. The annual report along with the notice was
dispatched on 30™ July, 2026.
Further, pursuant to Regulation 36(1)(b) of the Securities and Exchange Board of India (Listing
Obligations and Disclosure Requirements) Regulations, 2015, a letter providing the web-link of the
Annual Report, being sent to those members who have not registered their e-mail address, is available
on the Company’s website at https:/www.oxygentapharma.com/ .
This is for the information and records of the exchange, please.
Thanking You.
Yours faithfully,
For Oxygenta Pharmaceutical Limited
Balasubba Reddy Mamilla
Executive Director
(DIN: 01998852)
OXYGENTA PHARMACEUTICAL LIMITED (Subsidiary of VIRUPAKSHA ORGANICS LIMITED)
(An 1SO 9001:2015, ISO 14001:2018 and ISO 45001:2015 Certified Company)
Regd off.& Factory: Sy.No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist)-502 291, Telangana, INDIA. Tel: 08455-250080
Corp. Office: Level-1, Plot No. B1 & B2, IDA Gandhi Nagar, Kukatpally, Hyderabad — 500 037, Telangana, INDIA.
E-Mail id: info@oxygentapharma.com. Website: www.oxygentapharma.com,
Phone 040-23073417, CIN: L24110TG1990PLC012038
OXYGENTA
PHARMACEUTICAL LIMITED
33RD
ANNUAL REPORT
2025-26
OXYGENTA PHARMACEUTICAL LIMITED 33RD ANNUAL REPORT 2025-26
CORPORATE INFORMATION
BOARD OF DIRECTORS:
Mr. Balasubba Reddy Mamilla - Whole Time Director (DIN:01998852)
Mr. Chandra Mouliswar Reddy Gangavaram - Whole Time Director (DIN:00046845)
Mr. Sidda Reddy Kanuparthi - Independent Director (DIN:07156289)
Mrs. Vedavathi Gangavaram - Non-Executive Director (DIN:02870966)
Dr. Veera Reddy Arava - Independent Director (DIN:10832178)
Mrs. Sharvari Swapnil Shinde - Independent Director (DIN:11149764)
*Mr. Amireddy Venkatesu Reddy - Additional Director (Executive Category) (DIN:11087687)
*Mr. Janardhana Reddy Yeddula - Additional Director (Independent Category) (DIN:03207357)
*#Chief Financial Officer - Mr. Prasad Reddy Battinapatla
^Company Secretary and Compliance Officer - Ms. Kumkum Bajaj
*Appointed w.e.f. 23rd May, 2026.
*#Appointed w.e.f. 07th November, 2025.
^ Appointed w.e.f. 14th August, 2025.
Corporate Identity Number (CIN) - L24110TG1990PLC012038
ISIN - INE102E01018
REGISTERED OFFICE:
Survey No.252/1, Aroor Village,
Sadasivapet Mandal,
Medak District, Medak,
Telangana, India – 502291
CORPORATE OFFICE:
Level-1 Plot No B1 and B2,
IDA Gandhi Nagar, Balanagar Township,
Hyderabad, Rangareddy, Telangana, India, 500037
STATUTORY AUDITORS
M/s. A.M. Reddy & D.R. Reddy,
Chartered Accountants
H. No. 3-6-640/1/C, 4th floor,
Street no.9 Himayat Nagar,
Hyderabad, Telangana,
India -500029.
(Firm Registration No. 0090685)
SECRETARIAL AUDITORS
M/s. Aakanksha Dubey & Co
Practicing Company Secretaries,
H. No. 11-1-439/301,
3rd Floor, Baba Residency,
Sitaphalmandi, Secunderabad – 500061
(Firm Registration Number: S2025TS1021000)
INTERNAL AUDITORS
M/s. Suryachandra & Associates,
Chartered Accountants
Plot No 10, House no 8-3-315/8,
Beside MGM International School,
Maruthi Nagar, Yousufguda, Hyderabad- 500045
(Firm Registration No.004297S)
OXYGENTA PHARMACEUTICAL LIMITED 33RD ANNUAL REPORT 2025-26
COST AUDITORS
M/s. PCR & Associates,
Cost Accountants,
Plot No. 80/A, Flat No 402, 4th Floor,
Srinivasam Apartment, Western Hills,
Pragati Nagar Road, Opp. JNTU, Kukatpally,
Hyderabad, Telangana, India- 500085
(Firm Registration No. 000355)
BANKERS
Kotak Mahendra Bank Limited
CONSTITUTION OF COMMITTEES:
AUDIT COMMITTEE:
Mr. Sidda Reddy Kanuparthi - Chairman
Mrs. Sharvari Swapnil Shinde - Member
Dr. Veera Reddy Arava - Member
Mr. Chandra Mouliswar Reddy Gangavaram - Member
NOMINATION AND REMUNEARTION COMMITTEE:
Dr. Veera Reddy Arava - Chairman
Mr. Sidda Reddy Kanuparthi - Member
Mrs. Sharvari Swapnil Shinde - Member
STAKEHOLDER RELATIONSHIP COMMITTEE:
Dr. Veera Reddy Arava - Chairman
Mr. Sidda Reddy Kanuparthi - Member
Mrs. Sharvari Swapnil Shinde - Member
Mr. Balasubba Reddy Mamilla - Member
LISTED AT:
BSE Limited
REGISTRAR & SHARE TRANSFER AGENTS:
M/s. Venture Capital & Corporate Investments Private Ltd
AURUM, Door No.4-50/P-II/57/4F & 5F, Plot No.57, 4th & 5th Floors,
Jayabheri Enclave Phase– II, Gachibowli, Hyderabad – 500032
Contact No: +91 040 23818475 / +91 040 35164940
E-mail: investor.relations@vccipl.com
Website: https://www.vccipl.com/
CONTACT DETAILS:
Cell : 040-23073417
E-Mail : cs@oxygentapharma.com
Website: https://www.oxygentapharma.com/index.html
OXYGENTA PHARMACEUTICAL LIMITED 33RD ANNUAL REPORT 2025-26
NOTICE
Notice is hereby given that the 33rd Annual General Meeting of the members of Oxygenta Pharmaceutical
Limited will be held on Friday, 21st day of August, 2026 at 10:30 A.M. through Video Conferencing/ Other Audio
Visual Means (OAVM), to transact the following business:
ORDINARY BUSINESS:
1. To receive, consider and adopt the Audited Financial Statements of the Company for the financial year
ended 31st March 2026, together with the Reports of the Board of Directors and Auditor’s thereon.
2. To appoint a director in place of Mr. Balasubba Reddy Mamilla (DIN: 01998852), who retires by rotation and
being eligible, offers himself for re-appointment.
“RESOLVED THAT pursuant to the applicable provisions of Section 152 and other applicable provisions of
the Companies Act, 2013, Mr. Balasubba Reddy Mamilla (DIN: 01998852), who retires by rotation at this
meeting, be and is hereby reappointed as a Director of the Company, whose period of office shall be liable to
retire by rotation.”
SPECIAL BUSINESS:
3. TO APPOINT MR. AMIREDDY VENKATESU REDDY (DIN: 11087687) AS A DIRECTOR AND WHOLE-
TIME DIRECTOR OF THE COMPANY:
To consider and, if thought fit, to pass with or without modifications, the following resolution as a Special
Resolution:
“RESOLVED THAT pursuant to the provisions of Sections 152, 161 and any other applicable provisions of
the Companies Act, 2013, provisions of SEBI (LODR) Regulations, 2015 and the rules made thereunder
(including any statutory modification(s) or re-enactment thereof for the time being in force), Mr. Amireddy
Venkatesu Reddy (DIN: 11087687), who was appointed by the Board of Directors as an Additional Director
(Category: Executive Director) of the Company on recommendation of Nomination and Remuneration
Committee with effect from 23rd May, 2026 who holds office up to the date of this Annual General Meeting or
the last date on which the annual general meeting should have been held, whichever is earlier and who is
eligible for appointment and has consented to act as Director of the Company, be and is hereby appointed
as a Director of the Company, liable to retire by rotation.”
“RESOLVED FURTHER THAT pursuant to the provisions of Sections 196, 197, 203, and other applicable
provisions, if any, of the Companies Act, 2013 (the "Act") read with Schedule V to the Act, and the
Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any
statutory modification(s) or re-enactment(s) thereof for the time being in force), and Regulation 17(1) of the
SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and based on the
recommendations of the Nomination and Remuneration Committee and the Board of Directors, consent of
the members be and is hereby accorded for the appointment of Mr. Amireddy Venkatesu Reddy (DIN:
11087687) as Whole Time Director of the Company for a term of Three (3) years w.e.f. 23rd May, 2026 at a
rem
[Showing first 8,000 characters — download PDF for full document]